Steven D. Reich

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Hope S. Rugo, Roy S. Herbst, Glenn Liu et al. · Journal of Clinical Oncology · 2005 · 485 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study

Glenn Liu, Hope S. Rugo, George Wilding et al. · Journal of Clinical Oncology · 2005 · 260 citations

Medicine, Oncology, Pharmacology +15

Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial

Peter Heald, Marilyn A. Mehlmauer, Ann Martin et al. · Journal of the American Academy of Dermatology · 2003 · 161 citations

Medicine, Dermatology, Oncology +11

AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)

Brian I. Rini, Olivier Rixe, Ronald M. Bukowski et al. · Journal of Clinical Oncology · 2005 · 148 citations

Medicine, Oncology, Pharmacology +17

Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non–Small-Cell Lung Cancer

Fadlo R. Khuri, James R. Rigas, Robert A. Figlin et al. · Journal of Clinical Oncology · 2001 · 124 citations

Medicine, Oncology, Pharmacology +13